Form 4 for TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD
Accepted 2026-03-09 00:00:00 ET · period of report 2026-03-05 · accession 0001193125-26-098551 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-03-09 | 2026-03-05 | TEVA | Francis Richard D | Pres, CEO | M - OptEx | — | +42.5K | 1.19M | +4% | — |
| DT | 2026-03-09 | 2026-03-05 | TEVA | Francis Richard D | Pres, CEO | S - Sale+OE | $31.67 | -20.0K | 1.17M | -2% | -$634.2K |
| DT | 2026-03-09 | 2026-03-05 | TEVA | Francis Richard D | Pres, CEO | M - OptEx | $0.00 | -42.5K | 127.4K | -25% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2026-03-05 | M | A | 42,452 | — | 1,190,664 | D | — | — | (F1) The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. (F2) Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. |
| 2 | Common | Ordinary Shares | 2026-03-05 | S | D | 20,025 | $31.67 | 1,170,639 | D | — | — | (F1) The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. (F4) Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. (F5) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.26 to $32.34, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| 3 | Derivative | Restricted Share Units | 2026-03-05 | M | D | 42,452 | $0.00 | 127,359 | D | — · — to — | 42,452 Ordinary Shares | (F2) Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. (F6) Restricted share units were granted on March 5, 2025, with 42,452 vested on March 5, 2026, 42,452 vesting on each of March 5, 2027 and March 5, 2028, and 42,455 vesting on March 5, 2029. |